Log In Sign up
The largest database of trusted experimental protocols

Pe conjugated nkg2c

Manufactured by R&D Systems
Visit Supplier

PE-conjugated NKG2C is a flow cytometry antibody that binds to the NKG2C receptor, which is expressed on natural killer (NK) cells and a subset of T cells. This reagent can be used to identify and quantify NKG2C-positive cells in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Pecy7 conjugated anti cd56, by BioLegend (4 mentions) Ecd conjugated anti cd3, by Beckman Coulter (2 mentions) Pacific blue conjugated anti cd57, by BioLegend (2 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) K562 cell line, by American Type Culture Collection (2 mentions) Golgiplug protein transport inhibitor, by BD (2 mentions) Bv785 conjugated anti cd3 clone okt3, by BioLegend (2 mentions) Pe cf594 conjugated anti cd57, by BioLegend (2 mentions) Percp cy5.5 conjugated anti cd107a, by BioLegend (2 mentions) Af700 conjugated anti tnf, by BioLegend (2 mentions) Bv605 conjugated ifn γ, by BioLegend (2 mentions) Ficoll paque, by GE Healthcare (2 mentions) Golgistop, by BD (2 mentions)

Close spelling variants of this product

NKG2C-PE NKG2C

4 protocols using pe conjugated nkg2c

1

Adaptive NK Cells in CMV Reactivation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) from HCT recipients were isolated from peripheral blood samples by density gradient centrifugation and analyzed by fluorescence-activated cell sorting (FACS) using an LSR II (BD Biosciences). PBMCs from recipients that reactivated CMV were collected at viral diagnosis, at 2, 4 and 8 weeks after antiviral therapy and at 6 months and 1 year post-transplant. For recipients that were CMV seronegative or were CMV seropositive without viral reactivation, PBMCs were collected at day 100, 6 months and 1 year post-transplant. The following fluorescently conjugated antibodies were used for phenotypic analysis: ECD-conjugated anti-CD3 (Beckman Coulter; IM2705U), PECy7-conjugated anti-CD56 (BioLegend; 318318), Pacific Blue-conjugated anti-CD57 (BioLegend; 322316) and PE-conjugated NKG2C (R&D Systems FAB138P-025). For statistical comparisons of adaptive NK cell percentages and absolute counts between RIC and MA recipients, unpaired, two-sided t-tests calculated using GraphPad were used. Error bars represent SEM. GraphPad was used to calculate R2 values and associated p values for the correlation between absolute monocyte and lymphocyte counts and adaptive NK cell expansion in 28 CMV seropositive recipients.
Cichocki F., Cooley S., Davis Z., DeFor T.E., Schlums H., Zhang B., Brunstein C.G., Blazar B.R., Wagner J., Diamond D.J., Verneris M.R., Bryceson Y.T., Weisdorf D.J, & Miller J.S. (2015). CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia, 30(2), 456-463.
+ Open protocol
+ Expand
2

Functional Analysis of NK Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Buffy coats collected from 5 healthy CMV seropositive donors were obtained from Memorial Blood Bank (Minneapolis, MN). Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque (GE Healthcare) and cultured with K562 cells at a 2:1 (effector:target) ratio for 5 hours in RPMI media supplemented with 10% fetal bovine serum (Gibco). GolgiStop and GolgiPlug protein transport inhibitors (BD Biosciences) were added 1 hour into the assay. The following antibodies were used for functional analysis of NK cell subsets: BV785-conjugated anti-CD3 (clone OKT3; Biolegend), PECy7-conjugated anti-CD56 (BioLegend; 318318), PE-CF594-conjugated anti-CD57 (Biolegend; 359620), PE-conjugated NKG2C (R&D Systems; FAB138P-025), PerCP-Cy5.5-conjugated anti-CD107a (Biolegend; 328616), AF700-conjugated anti-TNF (Biolegend; 502928) and BV605-conjugated IFN-γ (Biolegend; 502536). The K562 cell line was purchased from ATCC (Manassas, Virginia) and is screened monthly for mycoplasma contamination. The experiment was performed at 2 independent times. Two-sided, paired t-tests in GraphPad were used to determine significance. Error bars represent SEM.
Cichocki F., Cooley S., Davis Z., DeFor T.E., Schlums H., Zhang B., Brunstein C.G., Blazar B.R., Wagner J., Diamond D.J., Verneris M.R., Bryceson Y.T., Weisdorf D.J, & Miller J.S. (2015). CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia, 30(2), 456-463.
+ Open protocol
+ Expand
3

Adaptive NK Cells in CMV Reactivation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells (PBMCs) from HCT recipients were isolated from peripheral blood samples by density gradient centrifugation and analyzed by fluorescence-activated cell sorting (FACS) using an LSR II (BD Biosciences). PBMCs from recipients that reactivated CMV were collected at viral diagnosis, at 2, 4 and 8 weeks after antiviral therapy and at 6 months and 1 year post-transplant. For recipients that were CMV seronegative or were CMV seropositive without viral reactivation, PBMCs were collected at day 100, 6 months and 1 year post-transplant. The following fluorescently conjugated antibodies were used for phenotypic analysis: ECD-conjugated anti-CD3 (Beckman Coulter; IM2705U), PECy7-conjugated anti-CD56 (BioLegend; 318318), Pacific Blue-conjugated anti-CD57 (BioLegend; 322316) and PE-conjugated NKG2C (R&D Systems FAB138P-025). For statistical comparisons of adaptive NK cell percentages and absolute counts between RIC and MA recipients, unpaired, two-sided t-tests calculated using GraphPad were used. Error bars represent SEM. GraphPad was used to calculate R2 values and associated p values for the correlation between absolute monocyte and lymphocyte counts and adaptive NK cell expansion in 28 CMV seropositive recipients.
Cichocki F., Cooley S., Davis Z., DeFor T.E., Schlums H., Zhang B., Brunstein C.G., Blazar B.R., Wagner J., Diamond D.J., Verneris M.R., Bryceson Y.T., Weisdorf D.J, & Miller J.S. (2015). CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia, 30(2), 456-463.
+ Open protocol
+ Expand
4

Functional Analysis of NK Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Buffy coats collected from 5 healthy CMV seropositive donors were obtained from Memorial Blood Bank (Minneapolis, MN). Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque (GE Healthcare) and cultured with K562 cells at a 2:1 (effector:target) ratio for 5 hours in RPMI media supplemented with 10% fetal bovine serum (Gibco). GolgiStop and GolgiPlug protein transport inhibitors (BD Biosciences) were added 1 hour into the assay. The following antibodies were used for functional analysis of NK cell subsets: BV785-conjugated anti-CD3 (clone OKT3; Biolegend), PECy7-conjugated anti-CD56 (BioLegend; 318318), PE-CF594-conjugated anti-CD57 (Biolegend; 359620), PE-conjugated NKG2C (R&D Systems; FAB138P-025), PerCP-Cy5.5-conjugated anti-CD107a (Biolegend; 328616), AF700-conjugated anti-TNF (Biolegend; 502928) and BV605-conjugated IFN-γ (Biolegend; 502536). The K562 cell line was purchased from ATCC (Manassas, Virginia) and is screened monthly for mycoplasma contamination. The experiment was performed at 2 independent times. Two-sided, paired t-tests in GraphPad were used to determine significance. Error bars represent SEM.
Cichocki F., Cooley S., Davis Z., DeFor T.E., Schlums H., Zhang B., Brunstein C.G., Blazar B.R., Wagner J., Diamond D.J., Verneris M.R., Bryceson Y.T., Weisdorf D.J, & Miller J.S. (2015). CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia, 30(2), 456-463.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!